Vaxcyte, Inc.

NasdaqGS:PCVX Stock Report

Market Cap: US$8.0b

Vaxcyte Management

Management criteria checks 2/4

Vaxcyte's CEO is Grant Pickering, appointed in Nov 2013, has a tenure of 12.33 years. total yearly compensation is $39.64M, comprised of 1.8% salary and 98.2% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $33.79M. The average tenure of the management team and the board of directors is 4.1 years and 5.2 years respectively.

Key information

Grant Pickering

Chief executive officer

US$39.6m

Total compensation

CEO salary percentage1.77%
CEO tenure12.3yrs
CEO ownership0.4%
Management average tenure4.1yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity

Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. What are the underlying business or industry changes driving this perspective?

Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside

Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on pneumococcal conjugate vaccines and a Group A Strep program, using a carrier sparing platform to target broad disease coverage. What are the underlying business or industry changes driving this perspective?

Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook

Catalysts About Vaxcyte Vaxcyte is a vaccine company developing pneumococcal conjugate vaccines and a Group A Strep candidate using a carrier sparing platform and large scale manufacturing infrastructure. What are the underlying business or industry changes driving this perspective?

Vaxcyte: Financial Durability And The Case For Disruption

Dec 16

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Jul 07
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Mar 31

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

Jan 15

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 06

CEO Compensation Analysis

How has Grant Pickering's remuneration changed compared to Vaxcyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$767m

Sep 30 2025n/an/a

-US$657m

Jun 30 2025n/an/a

-US$547m

Mar 31 2025n/an/a

-US$510m

Dec 31 2024US$40mUS$700k

-US$464m

Sep 30 2024n/an/a

-US$508m

Jun 30 2024n/an/a

-US$497m

Mar 31 2024n/an/a

-US$437m

Dec 31 2023US$12mUS$640k

-US$402m

Sep 30 2023n/an/a

-US$300m

Jun 30 2023n/an/a

-US$265m

Mar 31 2023n/an/a

-US$245m

Dec 31 2022US$14mUS$601k

-US$223m

Sep 30 2022n/an/a

-US$174m

Jun 30 2022n/an/a

-US$143m

Mar 31 2022n/an/a

-US$118m

Dec 31 2021US$5mUS$575k

-US$100m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$83m

Dec 31 2020US$3mUS$481k

-US$89m

Sep 30 2020n/an/a

-US$83m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$596kUS$426k

-US$50m

Compensation vs Market: Grant's total compensation ($USD39.64M) is above average for companies of similar size in the US market ($USD8.15M).

Compensation vs Earnings: Grant's compensation has increased whilst the company is unprofitable.

CEO

Grant Pickering (57 yo)

12.3yrs
Tenure
US$39,639,512
Compensation

Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...

Leadership Team

NamePositionTenureCompensationOwnership
Grant Pickering
Co-Founder12.3yrsUS$39.64m0.42%
$ 33.8m
Andrew Guggenhime
President & CFO5.8yrsUS$17.88m0.067%
$ 5.4m
James Wassil
Executive VP & COO6.3yrsUS$17.87m0.077%
$ 6.2m
Mikhail Eydelman
Senior VP3.9yrsUS$5.66m0.0088%
$ 704.9k
Jeff Fairman
Co-Founder & VP of Researchno datano datano data
Elvia Cowan
Senior VP of Finance & Chief Accounting Officerno datano data0.0069%
$ 552.8k
Jeff Macdonald
Executive Director of Investor Relationsno datano datano data
Whitney Jones
Chief People Officer2.2yrsno datano data
Janet Graesser
Senior Vice President of Corporate Affairs1.2yrsno datano data
Harp Dhaliwal
Chief Technical Operations Officer4.3yrsUS$1.84mno data
Sam Iki
Senior Vice President of Project Managementno datano datano data
Chris Griffith
Chief Business & Strategy Officerless than a yearno datano data
4.1yrs
Average Tenure
55yo
Average Age

Experienced Management: PCVX's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Grant Pickering
Co-Founder12.3yrsUS$39.64m0.42%
$ 33.8m
Annie Drapeau
Independent Director4.5yrsUS$510.02k0.0050%
$ 401.5k
Heath Lukatch
Independent Director7.8yrsUS$497.52k0.0098%
$ 792.6k
Halley Gilbert
Independent Director5.9yrsUS$510.02k0.0050%
$ 401.5k
Emmanuel Walter
Member of Scientific Advisory Boardno datano datano data
Carlos Paya
Independent Chairman of the Board4.4yrsUS$525.02k0.0050%
$ 401.5k
Anthony Ford-Hutchinson
Member of Scientific Advisory Boardno datano datano data
Jeffrey Almond
Member of Scientific Advisory Board9.2yrsno datano data
Teri Loxam
Independent Director4.5yrsUS$510.02k0.0050%
$ 401.5k
Emmanuel Hanon
Member of Scientific Advisory Boardno datano datano data
William Hausdorff
Member of Scientific Advisory Boardno datano datano data
Jacks Lee
Independent Director2.3yrsUS$500.02k0.0011%
$ 86.9k
5.2yrs
Average Tenure
58yo
Average Age

Experienced Board: PCVX's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/26 22:10
End of Day Share Price 2026/03/26 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vaxcyte, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Thomas ShraderBTIG
Carter GouldCantor Fitzgerald & Co.